Drug intelligence / Profile preview

Cicanacre+

Development stage: Preclinical
Lead developer: MEGA BIOPHARMA
Administration: Topical

Overview

Cicanacre+ is a topical wound care product and dermocosmetic developed by MEGA BIOPHARMA. It utilizes the company's proprietary Bionacre technology, specifically the NACR-45 formulation, which is derived from nacre (mother-of-pearl) extracted from large pearl oysters. This natural biomaterial is designed to support tissue regeneration, wound healing, and skin repair. Classified as a medical device, it is applied topically to affected areas to facilitate the skin's natural repair processes.

Brand names: Cicanacre+Cicanacre
Other names: NACR-45NACR45NACR 45

Beyond the preview

Go deeper on Cicanacre+.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cicanacre+.

Explore the full profile